0001183740-20-000212.txt : 20201005 0001183740-20-000212.hdr.sgml : 20201005 20201002194612 ACCESSION NUMBER: 0001183740-20-000212 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20201005 DATE AS OF CHANGE: 20201002 EFFECTIVENESS DATE: 20201005 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LexaGene Holdings Inc. CENTRAL INDEX KEY: 0001450416 IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0228 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-377062 FILM NUMBER: 201221978 BUSINESS ADDRESS: STREET 1: 500 CUMMINGS CTR., SUITE 4550 CITY: BEVERLY STATE: MA ZIP: 01915 BUSINESS PHONE: 800-215-1824 MAIL ADDRESS: STREET 1: 500 CUMMINGS CTR., SUITE 4550 CITY: BEVERLY STATE: MA ZIP: 01915 FORMER COMPANY: FORMER CONFORMED NAME: STONESHIELD CAPITAL CORP. DATE OF NAME CHANGE: 20100729 FORMER COMPANY: FORMER CONFORMED NAME: STONESHIELD CAPITAL CORP DATE OF NAME CHANGE: 20081119 D 1 primary_doc.xml X0708 D LIVE 0001450416 LexaGene Holdings Inc. 500 CUMMINGS CTR., SUITE 4550 BEVERLY MA MASSACHUSETTS 01915 800-215-1824 BRITISH COLUMBIA, CANADA Wolfeye Resource Corp. STONESHIELD CAPITAL CORP. STONESHIELD CAPITAL CORP Corporation true John (Jack) Regan 500 Cummings Ctr., Suite 4550 Beverly MA MASSACHUSETTS 01915 Executive Officer Director Daryl Rebeck 500 Cummings Ctr., Suite 4550 Beverly MA MASSACHUSETTS 01915 Executive Officer Director Tom Slezak 500 Cummings Ctr., Suite 4550 Beverly MA MASSACHUSETTS 01915 Director Manohar Furtado 500 Cummings Ctr., Suite 4550 Beverly MA MASSACHUSETTS 01915 Director Joseph Caruso 500 Cummings Ctr., Suite 4550 Beverly MA MASSACHUSETTS 01915 Director Jeffrey Mitchell 500 Cummings Ctr., Suite 4550 Beverly MA MASSACHUSETTS 01915 Executive Officer Biotechnology Decline to Disclose 06b false 2020-09-09 true true true true true Unit comprised of a share and one-half of one warrant. Each whole warrant is exercisable into a share at C$1.10 per share until September 9, 2023. false 0 1659999 1007857 652142 Total Offering Amount equals the price of units (1562000 x C$0.85), plus the aggregate exercise price of the underlying warrants (781000 x C$1.10), converted at US$1:C$1.3173. There is no assurance that the warrants, expiring 9/9/2023, will be exercised. false 4 0 0 0 false LexaGene Holdings Inc. /s/ Jeffrey Mitchell Jeffrey Mitchell CFO 2020-10-02